An interventional study of RQ guided nutrition and Standard Treatment (Guideline-Based) in Nutritional Therapy in an ICU and Critically Ill Patients Requiring Mechanical Ventilation, sponsored by Poznan University of Medical Sciences. Recruiting at 1 site in Poland. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Poznan University of Medical Sciences · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Introduction and assumptions:
Optimal nutritional therapy is an important component of intensive care. Both underfeeding and overfeeding are associated with poorer outcomes in critically ill patients. Indirect calorimetry is the gold standard for assessing resting energy expenditure (REE). It also provides the respiratory quotient (RQ), calculated as carbon dioxide production divided by oxygen consumption. RQ reflects substrate utilization and may help guide the choice of nutritional formulations. The RQCal study evaluates whether using RQ in addition to REE improves clinical outcomes in mechanically ventilated ICU patients.
Methodology:
This is a single-center, prospective, randomized controlled trial in adult ICU patients receiving invasive mechanical ventilation with an anticipated duration of more than 48 hours. Participants are allocated 1:1 to standard nutritional therapy guided by indirect calorimetry and REE, or to the same therapy with additional RQ-guided selection of nutritional formulations. In the intervention group, formulations are selected according to predefined RQ categories (\<0.80, 0.80-0.85, and >0.85). Laboratory parameters related to nutritional and metabolic status are assessed during routine care.
The primary outcome is 28-day ventilator-free days (VFD), defined as days alive and free from invasive mechanical ventilation within 28 days after randomization; patients who die before day 28 or remain invasively ventilated throughout this period receive 0 VFD. Secondary outcomes include 28-day survival, survival to ICU and hospital discharge, ICU length of stay, ventilator-associated pneumonia, illness severity scores, and laboratory parameters. The maximum planned enrollment is 240 participants (120 per group).
The primary efficacy analysis follows the intention-to-treat principle, estimating the between-group difference in mean VFD using a linear model with HC3 robust standard errors. The Mann-Whitney U test is a sensitivity analysis; a supportive analysis includes participants ventilated for more than 48 hours.
Study period: October 2024 to September 2027.
Inclusion criteria: Age 18-85 years; ICU treatment; invasive mechanical ventilation with an anticipated need for more than 48 hours; universal health insurance.
Exclusion criteria: ECMO; FiO2 >60%; no invasive mechanical ventilation; expected survival under 48 hours; pregnancy; age \<18 or >85 years; prisoners transferred from penal institutions; significant gastrointestinal disorders preventing standard nutritional therapy.
Interim analyses and discontinuation:
Two interim efficacy analyses are planned at approximately 80 and 160 randomized participants with available primary-outcome data, using a Lan-DeMets alpha-spending function approximating O'Brien-Fleming boundaries to control the overall two-sided type I error rate at 0.05. The trial may be stopped early for compelling efficacy or significant safety concerns; no formal futility stopping is planned. Individual nutritional interventions may be discontinued for intolerance or clinical reasons, but all randomized participants remain in the primary intention-to-treat analysis.
Expected results:
RQ-guided selection of nutritional formulations may improve metabolic and nutritional management and increase 28-day VFD, with potential benefits for secondary clinical outcomes. Findings may inform nutritional treatment strategies for other ICUs.
Poznan University of Medical Sciences is the lead sponsor of 152 studies on the registry; 42 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Nov 18, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other: Standard Treatment (Guideline-Based)
Other: RQ guided nutrition
In the study group, nutritional preparations will be additionally systematized and selected for each patient depending on their RQ value, and caloric requirements will be controlled by indirect calorimetry and REE, as in the control group.
Standard nutritional treatment according to ESPEN guidelines, guided by indirect calorimetry and REE, without using RQ for the selection of nutritional formulations.
28-day ventilator-free days (VFD)
Number of days alive and free from invasive mechanical ventilation during the first 28 days after randomization. A period of at least 24 consecutive hours free from invasive mechanical ventilation is required to qualify as a ventilator-free day. Participants who die before day 28 or require invasive mechanical ventilation for 28 days or longer will be assigned 0 VFD.
Time frame: First 28 days after randomization.
28-day survival rate
Survival status at 28 days after randomization.
Time frame: 28 days after randomization.
Survival rate in an ICU.
If the patient survives until discharge from an ICU after initial admission to ICU and inclusion in the study.
Time frame: From initial admission to the ICU and inclusion in the study to discharge from the ICU, assessed up to 120 days from the randomisation.
Survival rate until hospital discharge.
If the patient survives until hospital discharge after initial admission to ICU and inclusion in the study.
Time frame: From initial admission to ICU and inclusion in the study to hospital discharge, assessed up to 120 days from the randomisation.
Length of stay in the ICU.
Measured total length of stay in the ICU until discharge from the ICU.
Time frame: From initial ICU admission to ICU discharge or death, assessed up to 120 days after randomization.
Ventilator-associated pneumonia (VAP)
Occurrence of VAP during ICU stay
Time frame: From initial admission to the ICU and inclusion in the study to discharge from the ICU, monitored up to 120 days from the randomisation.
Sequential Organ Failure Assessment (SOFA) score
Measurement of Sequential Organ Failure Assessment (SOFA) score , on a day of admission and on days 3., 7., and 10. from initial admission and inclusion in the study. The scale ranges from 0 to 24 points, where 0 represents the lowest predicted mortality and 24 represents the highest predicted mortality.
Time frame: Measurements on a day of admission and on days 3., 7., and 10. from initial admission and inclusion in the study.
Acute Physiology and Chronic Health Evaluation II (APACHE II) score
Measurement of Acute Physiology and Chronic Health Evaluation II (APACHE II) score , on a day of admission and on days 3., 7., and 10. from initial admission and inclusion in the study. The scale ranges from 0 to 71 points, where 0 represents the lowest predicted mortality and 71 represents the highest predicted mortality.
Time frame: Measurements on a day of admission and on days 3., 7., and 10. from initial admission and inclusion in the study.
Simplified Acute Physiology Score II (SAPS II)
Measurement of Simplified Acute Physiology Score II (SAPS II) , on a day of admission and on days 3., 7., and 10. from initial admission and inclusion in the study. The scale ranges from 0 to 163 points, where 0 represents the lowest predicted mortality and 163 represents the highest predicted mortality.
Time frame: Measurements on a day of admission and on days 3., 7., and 10. from initial admission and inclusion in the study.
Plan to share: Yes — De-identified individual participant data may be made available upon reasonable request to the corresponding author, following assessment by the study supervisors and approval by the principal investigator.
Supporting information: Study protocol
Time frame: Data will be available after completion of the study and publication of the final study results.
Access criteria: Access may be granted to qualified researchers upon reasonable request to the corresponding author, following assessment of the request by the study supervisors and approval by the principal investigator.
Started Oct 2024 (actual). Primary completion is estimated for Sep 2027, 35 months after the start.
Completion moved once since we started tracking on Sep 25, 2026: Oct 2027 → Dec 2027, on Nov 18, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Poznan University of Medical Sciences →